Scar News and Research RSS Feed - Scar News and Research

Study show that silymarin may be a useful treatment for NASH

Results from a double-blind, placebo-controlled study of silymarin, which is derived from the milk thistle plant, have shown that this herbal remedy may be a useful treatment option for non-alcoholic steatohepatitis (NASH). [More]
Diabetes drug liraglutide could prove to be a new treatment option for NASH

Diabetes drug liraglutide could prove to be a new treatment option for NASH

A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver Congress 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis. [More]
Study supports use of vitamin E as effective treatment for NASH

Study supports use of vitamin E as effective treatment for NASH

Results revealed today at The International Liver Congress 2015 show that vitamin E (d-alpha-tocopherol) is an effective treatment for non-alcoholic steatohepatitis (NASH). NASH occurs when the liver becomes inflamed due to the accumulation of fat. Over time, persistent inflammation can lead to the formation of fibrous scar tissue in the liver and around its blood vessels, which can eventually cause cirrhosis. [More]

Capsaicin has beneficial effects on liver damage, study reveals

Results revealed today at the International Liver Congress 2015 show that the daily consumption of capsaicin, the active compound of chilli peppers, was found to have beneficial effects on liver damage. [More]
Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill). [More]
Study reveals new target for research into liver disease

Study reveals new target for research into liver disease

In a recent study, Virginia Commonwealth University School of Medicine researchers predicted which cirrhosis patients would suffer inflammations and require hospitalization by analyzing their saliva, revealing a new target for research into a disease that accounts for more than 30,000 deaths in the United States each year. [More]
Manchester scientists develop enhanced surface for silicone breast implants

Manchester scientists develop enhanced surface for silicone breast implants

Scientists at The University of Manchester have created an enhanced surface for silicone breast implants which could reduce complications and make them less likely to be rejected by the body. [More]
New approach to improve cardiac regeneration

New approach to improve cardiac regeneration

The heart tissue of mammals has limited capacity to regenerate after an injury such as a heart attack, in part due to the inability to reactivate a cardiac muscle cell and proliferation program. Recent studies have indicated a low level of cardiac muscle cell (cardiomyocytes) proliferation in adult mammals, but it is insufficient to repair damaged hearts. [More]
Study compares latest drug-coated stents with traditional bypass surgery

Study compares latest drug-coated stents with traditional bypass surgery

Newer drug-coated stents that keep arteries open have similar long-term rates of death compared with traditional bypass surgery for patients with more than one diseased coronary artery. [More]
Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program. [More]
Cancer drug promotes neuronal regeneration after spinal cord injury

Cancer drug promotes neuronal regeneration after spinal cord injury

Damage to the spinal cord rarely heals because the injured nerve cells fail to regenerate. The regrowth of their long nerve fibers is hindered by scar tissue and molecular processes inside the nerves. [More]
Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

CTI BioPharma Corp. and Baxter International Inc. today announced positive top-line results for the primary endpoint from PERSIST-1, the randomized, controlled Phase 3 registration clinical trial examining pacritinib, a next generation oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis. [More]
Covalon announces introduction of new MediClear product line to reduce surgical site infections

Covalon announces introduction of new MediClear product line to reduce surgical site infections

Covalon Technologies Ltd, an advanced medical technologies company, today announced the introduction of its new MediClear product line designed to significantly improve patient compliance with efforts to reduce surgical site infections (SSI). [More]
Single-site laparoscopic surgery effective for colorectal cancer

Single-site laparoscopic surgery effective for colorectal cancer

Colorectal cancer may be highly preventable, yet it is second only to lung cancer in the number of lives it takes nationwide each year. [More]
Scientists detect new molecule that contributes to development of liver fibrosis

Scientists detect new molecule that contributes to development of liver fibrosis

Liver fibrosis, which is the progressive formation of scar tissue in the liver, is a massive medical problem. An estimated ten percent of the population is affected by liver fibrosis or its corresponding later stage, liver cirrhosis. A variety of causes can lead to liver fibrosis, the most widely recognized ones being alcohol consumption and virus-induced chronic liver inflammation. [More]
Possible cause of liver disease identified in adolescents with cystic fibrosis

Possible cause of liver disease identified in adolescents with cystic fibrosis

A professor at the University of Colorado School of Medicine at the Anschutz Medical Campus and his colleagues have found a possible cause of liver disease in adolescents with cystic fibrosis. [More]
Rutgers patient gets second chance at life following liver transplant

Rutgers patient gets second chance at life following liver transplant

Mati Muñoz is 65 years old - filled with the enthusiastic energy that comes with a second chance at life. A decade ago, says Muñoz, who lives in Woodbridge Township, N.J., her liver was being destroyed by hepatitis C, a viral disease she believes she contracted as a girl in her native Cuba from a poorly sterilized needle used in a medical procedure. [More]
Xenics and VUmc collaborate in thermography project for clinical research

Xenics and VUmc collaborate in thermography project for clinical research

Xenics, Europe's leading developer and manufacturer of advanced infrared imagers, cameras and customized imaging solutions from the LWIR to the visible realm, is collaborating in path breaking clinical research programs with the VU University Medical Center of Amsterdam, The Netherlands. [More]
Loyola orthopaedic surgeon uses new minimally invasive technique to repair ruptured Achilles tendon

Loyola orthopaedic surgeon uses new minimally invasive technique to repair ruptured Achilles tendon

Orthopaedic surgeon Adam Schiff, MD, of Loyola University Medical Center, used a new minimally invasive technique to repair the ruptured Achilles tendon on Mr. Frias' left leg. The technique requires a smaller incision, minimizes wound healing complications and leaves less scar tissue. [More]
Researchers develop new MRI-based technique to better detect NAFLD in children

Researchers develop new MRI-based technique to better detect NAFLD in children

Between 5 and 8 million children in the United States have nonalcoholic fatty liver disease (NAFLD), yet most cases go undiagnosed. To help address this issue, researchers at UC San Diego School of Medicine have developed a new magnetic resonance imaging (MRI)-based technique to help clinicians and researchers better detect and evaluate NAFLD in children. [More]
Advertisement
Advertisement